Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126244872 | 12624487 | 2 | F | 20160728 | 20160809 | 20160805 | 20160818 | EXP | JP-TAKEDA-2016TJP015950 | TAKEDA | 67.00 | YR | M | Y | 0.00000 | 20160818 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126244872 | 12624487 | 1 | PS | ACTOS | PIOGLITAZONE HYDROCHLORIDE | 1 | Oral | 30 MG, QD | 14100 | MG | N | 21073 | 30 | MG | TABLET | QD | |||
| 126244872 | 12624487 | 2 | SS | ACTOS | PIOGLITAZONE HYDROCHLORIDE | 1 | Oral | 30 MG, QD | 14100 | MG | N | 21073 | 30 | MG | TABLET | QD | |||
| 126244872 | 12624487 | 3 | SS | METACT | METFORMIN HYDROCHLORIDEPIOGLITAZONE HYDROCHLORIDE | 1 | Oral | 1 DF, QD | 0 | 1 | DF | TABLET | QD | ||||||
| 126244872 | 12624487 | 4 | C | AMARYL | GLIMEPIRIDE | 1 | Oral | 1 MG, BID | U | 0 | 1 | MG | TABLET | BID | |||||
| 126244872 | 12624487 | 5 | C | METGLUCO | METFORMIN HYDROCHLORIDE | 1 | Oral | 250 MG, TID | U | 0 | 250 | MG | TABLET | TID | |||||
| 126244872 | 12624487 | 6 | C | SEIBULE | MIGLITOL | 1 | Oral | 75 MG, TID | U | 0 | 75 | MG | TABLET | TID | |||||
| 126244872 | 12624487 | 7 | C | TENELIA | TENELIGLIPTIN | 1 | Oral | 20 MG, QD | U | 0 | 20 | MG | TABLET | QD | |||||
| 126244872 | 12624487 | 8 | C | ADALAT | NIFEDIPINE | 1 | Oral | 40 MG, QD | U | 0 | 40 | MG | TABLET | QD | |||||
| 126244872 | 12624487 | 9 | C | ARTIST | CARVEDILOL | 1 | Oral | 10 MG, QD | U | 0 | 10 | MG | TABLET | QD | |||||
| 126244872 | 12624487 | 10 | C | BAYASPIRIN | ASPIRIN | 1 | Oral | 100 MG, QD | U | 0 | 100 | MG | TABLET | QD | |||||
| 126244872 | 12624487 | 11 | C | GLUCOBAY | ACARBOSE | 1 | Oral | 50 MG, UNK | U | 0 | 50 | MG | TABLET | ||||||
| 126244872 | 12624487 | 12 | C | JANUVIA | SITAGLIPTIN PHOSPHATE | 1 | Oral | 50 MG, QD | U | 0 | 50 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126244872 | 12624487 | 1 | Diabetes mellitus |
| 126244872 | 12624487 | 3 | Diabetes mellitus |
| 126244872 | 12624487 | 4 | Diabetes mellitus |
| 126244872 | 12624487 | 5 | Diabetes mellitus |
| 126244872 | 12624487 | 6 | Diabetes mellitus |
| 126244872 | 12624487 | 7 | Diabetes mellitus |
| 126244872 | 12624487 | 8 | Hypertension |
| 126244872 | 12624487 | 9 | Hypertension |
| 126244872 | 12624487 | 10 | Thrombosis prophylaxis |
| 126244872 | 12624487 | 11 | Diabetes mellitus |
| 126244872 | 12624487 | 12 | Diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126244872 | 12624487 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126244872 | 12624487 | Bladder neoplasm |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126244872 | 12624487 | 1 | 20070602 | 201207 | 0 | |
| 126244872 | 12624487 | 2 | 20150416 | 20160728 | 0 | |
| 126244872 | 12624487 | 3 | 201207 | 20150415 | 0 | |
| 126244872 | 12624487 | 4 | 20030531 | 0 | ||
| 126244872 | 12624487 | 5 | 20150416 | 0 | ||
| 126244872 | 12624487 | 6 | 20100116 | 0 | ||
| 126244872 | 12624487 | 7 | 20150416 | 0 | ||
| 126244872 | 12624487 | 11 | 200010 | 20100115 | 0 | |
| 126244872 | 12624487 | 12 | 201102 | 20150415 | 0 |